MX2022010921A - Compuestos para su uso en afecciones inflamatorias. - Google Patents

Compuestos para su uso en afecciones inflamatorias.

Info

Publication number
MX2022010921A
MX2022010921A MX2022010921A MX2022010921A MX2022010921A MX 2022010921 A MX2022010921 A MX 2022010921A MX 2022010921 A MX2022010921 A MX 2022010921A MX 2022010921 A MX2022010921 A MX 2022010921A MX 2022010921 A MX2022010921 A MX 2022010921A
Authority
MX
Mexico
Prior art keywords
compounds
inflammatory conditions
inflammation
toll
receptors
Prior art date
Application number
MX2022010921A
Other languages
English (en)
Spanish (es)
Inventor
Marín Pablo Avilés
González Alejandro Losada
Muñoz Salvador Fudio
Sousa-Faro José Maria Fernández
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of MX2022010921A publication Critical patent/MX2022010921A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022010921A 2020-03-02 2021-03-02 Compuestos para su uso en afecciones inflamatorias. MX2022010921A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP20382152 2020-03-02
EP20382192 2020-03-13
EP20382266 2020-04-02
EP20382339 2020-04-27
EP20382816 2020-09-16
EP20382815 2020-09-16
EP21382059 2021-01-25
PCT/EP2021/055187 WO2021175857A1 (en) 2020-03-02 2021-03-02 Compounds for use in inflammatory conditions

Publications (1)

Publication Number Publication Date
MX2022010921A true MX2022010921A (es) 2022-09-29

Family

ID=74732953

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022010921A MX2022010921A (es) 2020-03-02 2021-03-02 Compuestos para su uso en afecciones inflamatorias.
MX2022010926A MX2022010926A (es) 2020-03-02 2021-03-02 Compuestos para su uso en infecciones viricas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022010926A MX2022010926A (es) 2020-03-02 2021-03-02 Compuestos para su uso en infecciones viricas.

Country Status (17)

Country Link
US (2) US12630589B2 (cg-RX-API-DMAC7.html)
EP (2) EP4114433A2 (cg-RX-API-DMAC7.html)
JP (2) JP2023517536A (cg-RX-API-DMAC7.html)
KR (2) KR20220151643A (cg-RX-API-DMAC7.html)
CN (2) CN115666616A (cg-RX-API-DMAC7.html)
AU (2) AU2021232535A1 (cg-RX-API-DMAC7.html)
BR (2) BR112022016604A2 (cg-RX-API-DMAC7.html)
CA (2) CA3169540A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022002396A1 (cg-RX-API-DMAC7.html)
CO (2) CO2022014031A2 (cg-RX-API-DMAC7.html)
IL (2) IL296069A (cg-RX-API-DMAC7.html)
MX (2) MX2022010921A (cg-RX-API-DMAC7.html)
PE (2) PE20230412A1 (cg-RX-API-DMAC7.html)
PY (2) PY2117301A (cg-RX-API-DMAC7.html)
TW (2) TW202144381A (cg-RX-API-DMAC7.html)
UY (2) UY39110A (cg-RX-API-DMAC7.html)
WO (2) WO2021175831A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4114436A1 (en) * 2020-03-02 2023-01-11 Pharma Mar S.A. Compounds for use in the treatment of coronavirus infection
CN115666616A (zh) 2020-03-02 2023-01-31 法马马有限公司 用于病毒感染的化合物
IL296067A (en) * 2020-03-02 2022-11-01 Pharma Mar Sa Pld for use in combination in the treatment of coronavirus
WO2024165764A1 (en) * 2023-02-10 2024-08-15 Pharma Mar, S.A. Plitidepsin for use in the treatment of non-integrated dna viral infections
CN117285611B (zh) * 2023-11-24 2024-02-09 中国海洋大学 一种来源于海鞘的抗炎寡肽及其在制备药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US20030148933A1 (en) * 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
BR9909668A (pt) * 1998-04-14 2000-12-19 Jomaa Hassan Uso de compostos de organofósforo para o tratamento terapêutico e profilático de infecções
ES2272462T3 (es) 2000-04-07 2007-05-01 The Trustees Of The University Of Pennsylvania Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso.
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
JP4623931B2 (ja) * 2000-12-07 2011-02-02 エンセラデュス、ファーマシューティカルズ、ベスローテン、フェンノートシャップ 炎症性疾患の治療用組成物
US20070148192A1 (en) * 2003-02-21 2007-06-28 Laddha Ritu N Stable ophthalmic composition
AU2004224418A1 (en) 2003-03-21 2004-10-07 Madeleine M. Joullie Tamandarin analogs and fragments thereof and methods of making and using
HUE028055T2 (en) * 2006-02-28 2016-11-28 Pharma Mar Sa Improved treatment of myeloma multiplex
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds
JP5814933B2 (ja) * 2009-12-15 2015-11-17 ノバルティス アーゲー 免疫増強化合物の均質な懸濁物およびその使用
US20120040033A1 (en) * 2010-08-10 2012-02-16 Ernest Timothy Armstrong Anti-infective mangrove extract against viruses, bacteria and fungi
GB201316524D0 (en) * 2013-09-17 2013-10-30 Medical Res Council Biomarkers
JP2017526728A (ja) * 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
US11771739B2 (en) * 2017-06-16 2023-10-03 Vanderbilt University Methods and compositions for treating microbial inflammation
CN115666616A (zh) * 2020-03-02 2023-01-31 法马马有限公司 用于病毒感染的化合物

Also Published As

Publication number Publication date
CO2022014093A2 (es) 2022-11-18
KR20220151643A (ko) 2022-11-15
PE20230606A1 (es) 2023-04-10
BR112022016675A2 (pt) 2022-10-11
JP2023517535A (ja) 2023-04-26
CN115461067A (zh) 2022-12-09
PY2117301A (es) 2022-08-09
PE20230412A1 (es) 2023-03-07
UY39110A (es) 2021-09-30
US20230295236A1 (en) 2023-09-21
WO2021175831A2 (en) 2021-09-10
US20230159594A1 (en) 2023-05-25
CO2022014031A2 (es) 2022-10-21
EP4114433A2 (en) 2023-01-11
CN115666616A (zh) 2023-01-31
AU2021232535A1 (en) 2022-10-06
WO2021175831A3 (en) 2021-10-14
UY39109A (es) 2021-09-30
BR112022016604A2 (pt) 2022-10-11
IL296069A (en) 2022-11-01
CA3169544A1 (en) 2021-09-10
US12630589B2 (en) 2026-05-19
EP4114435A1 (en) 2023-01-11
TWI908772B (zh) 2025-12-21
WO2021175857A1 (en) 2021-09-10
KR20220150350A (ko) 2022-11-10
IL296068A (en) 2022-11-01
TW202146038A (zh) 2021-12-16
CL2022002396A1 (es) 2023-06-30
JP2023517536A (ja) 2023-04-26
CL2022002395A1 (es) 2023-06-30
AU2021231197A1 (en) 2022-10-06
MX2022010926A (es) 2022-09-29
TW202144381A (zh) 2021-12-01
PY2117308A (es) 2022-08-09
CA3169540A1 (en) 2021-09-10

Similar Documents

Publication Publication Date Title
UY39109A (es) Compuestos para su uso en afecciones inflamatorias
MX2021006804A (es) Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
DOP2013000036A (es) Derivados de ciclobutano como inhibidores de jak
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
EA202190974A1 (ru) Противовирусные пролекарства и их наносоставы
PA8805801A1 (es) Agonistas novedosos de los receptores de glucorticoides
PE20160167A1 (es) Composiciones y metodos para alterar la senalizacion del segundo mensajero
GT201300128A (es) Variantes de fc silenciosas de los anticuerpos anti-cd40
DOP2011000217A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
CR8704A (es) Compuestos de imidazol
ECSP10010438A (es) ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS Y METODOS DE USO
CR20150296A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
CR8730A (es) Compuestos de metil-aril o heteroaril- amida sustituida
CL2011001967A1 (es) Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico.
CO6341558A2 (es) Antagonistas del recepptor de nmda para el tratamiento de trastornos neuropsiquiatricos
CO6341625A2 (es) Derivados de indol como agentes anticáncer
MX2018005589A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
GT201500235A (es) Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3)
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CO6531479A2 (es) Derivados de espirolactama y uso de los mismos
AR106981A1 (es) Una composición antimicrobiana
CO6541592A2 (es) Tiazoles biciclicos como moduladores alostericos de receptores de mglur5
PA8782701A1 (es) Antagonistas del receptor de urotensina ii
CR20110023A (es) Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida